
Swiss Novartis has lit a fire under its sales of Genmab-developed multiple sclerosis drug Kesimpta, evidenced by Novartis’s financial report for the first quarter of the year.
Kesimpta sales totaled USD 195m at the end of the first three months of 2022, compared to USD 50m at the conclusion of Q1, 2021.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app